Physician profile
Dawei Yang
NPI 1922087477
$30,780.81
in general payments reported to CMS, 2019-2025
39 companies · $8,288 in 2025
The $8,288 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $289 · 2021: $976 · 2022: $1,612 · 2023: $1,792 · 2024: $17K · 2025: $8,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $7,344 · Honoraria: $3,870 · Travel and Lodging: $2,342 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,330.00 |
| Food and Beverage | $7,344.19 |
| Honoraria | $3,870.00 |
| Travel and Lodging | $2,341.59 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $15,543.56 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $5,363.44 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $2,413.59 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,140.61 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Celgene Corporation | $895.28 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $801.48 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $760.07 | 2019-2025 | |
| Gilead Sciences, INC. | $622.92 | 2019-2025 | |
| Janssen Biotech, INC. | $554.76 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Genzyme Corporation | $439.76 | 2023-2025 | |
| Lilly USA, LLC | $230.85 | 2023-2025 | Omvoh, Zepbound |
| Regeneron Healthcare Solutions, INC. | $221.05 | 2022-2024 | Dupixent |
| Fresenius Kabi USA, LLC | $210.90 | 2024-2025 | Idacio, Adalimumab-Aacf |
| Intercept Pharmaceuticals, INC. | $192.88 | 2019-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $168.57 | 2019-2024 | Dificid, Zinplava |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawei Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.